Updated on 25 June 2013
There were published article that it cannot be done so we swam in the opposite current. We worked in a small team as compared to today's pharmaceutical laboratories where the size of team is really big. One has to be smart. One has to stand up to convictions, which lacks in youngsters today. They don't have the patience to accept fall outs. A good drug dies five times before it goes to the market.
Tell us about the activities taking place in D3. What success has been achieved so far?
D3-Drug Discovery and Development, is a virtual company that develops drugs, goes into preclinical and clinical trials, and can go up to proof-of-concept level. A team of experts in D3 focus on taking projects through the development process from preclinical development candidates to 'proof-of-concept' (PoC) studies in humans, with the overall goal of developing treatment modalities for Singaporean patients, generating major economic benefit through licenses and potentially creating new intellectual property. D3 translates R&D for biomedical discoveries made in Singapore and is striving to build a seamless value chain from biomedical discovery, or even a mere concept, to a clinical application.
By working closely with other A*STAR institutes, D3 is building a bridge between basic science and clinical translation. D3 also collaborates with other research groups in Singapore, such as Singapore Clinical Research Institute (SCRI), Investigational Medicine Units of the Singapore Health Services, Changi General Hospital and National University Health System, as well as industry partners.
In the first half of 2013, D3 advanced into an H1N1 influenza virus-like particle vaccine project from preclinical to clinical development. Jointly developed with the ETC, the Singapore Immunology Network (SIgN), the Duke-NUS Graduate Medical School (Duke-NUS), the DSO National Laboratories and biopharmaceutical company Cytos Biotechnology, the project enabled a collaboration between D3 and the ETC.
D3 enables a seamless transition of a molecule preclinical target identification, assay development, lead optimization to preclinical-development activities. Anybody with novel molecule identification that can go up to pre-clinical trial can approach D3 and if it is a worthwhile project, then it can be adopted for further progress.